ABx Group has lodged a prospectus for a fully underwritten $2 million share purchase plan, forming part of a broader $4.1 million capital raising for its Deep Leads rare earths project and ALCORE pilot plant. The offer gives eligible shareholders discounted shares and options, but leaves the final price unknown until after applications close and remains subject to shareholder approval.
- $2 million fully underwritten SPP at the lower of 3.1 cents or 95% of five-day VWAP
- One unquoted option for every two SPP shares, exercisable at 4.6 cents
- Capital raising intended to fund Deep Leads, ALCORE, working capital and costs
- Non-participating shareholders face approximately 12.7% dilution under the stated assumptions
- Shareholder approval required at the 29 October general meeting
ABx sets terms for $2 million shareholder offer
ABx Group Limited (ASX:ABX) has put the legal machinery behind its $2 million share purchase plan, giving eligible Australian and New Zealand shareholders access to shares at the lower of $0.031 or 95% of the five-day VWAP through to the closing date. The offer is fully underwritten by Alpine Capital, but the actual price and number of shares will not be known when investors apply.
The SPP forms the second leg of an approximately $4.1 million capital raising. ABx has already issued 64.52 million placement shares at $0.031 each, alongside 806,452 shares issued to nominees of the lead manager as a success fee. A further 3.23 million shares proposed for director Ian Levy still require shareholder approval.
Options add leverage and complexity
Participants can apply for between $1,000 and $30,000 of SPP shares and will receive one free unquoted option for every two shares issued. Those options carry a $0.046 exercise price and expire three years after issue. The company may accept oversubscriptions, while any shortfall within the $2 million underwriting amount can be taken up by Alpine Capital or its nominees on the same share and option terms.
The prospectus also proposes options for placement participants and the lead manager, plus a separate fee package for the underwriter. That package deserves careful scrutiny: earlier sections describe the Underwriter Options as carrying a $0.046 exercise price and three-year term, while the detailed terms section says they will match the existing quoted ABXO class, with a $0.10 exercise price and expiry on 17 November 2027. The prospectus does not resolve that apparent inconsistency.
Deep Leads and ALCORE are the funding targets
ABx says the combined proceeds will go towards progressing the Deep Leads rare earths project in Tasmania, constructing and commissioning the ALCORE pilot plant, working capital and capital-raising costs. On the company’s pro forma assumptions, cash and equivalents would rise from $600,000 at 30 June 2026 to about $4.61 million after the placement, SPP and estimated costs.
The company says that cash position should fund activities until approximately April 2027, subject to the factors outlined in the prospectus. That runway is important because the filing also records a $2.191 million net loss after tax and $4.071 million of operating and investing cash outflows for the six months to 30 June 2026. ABx warns that its ability to continue as a going concern depends on additional capital, asset realisations, project development and progress in its research and development initiatives.
Dilution remains the immediate shareholder trade-off
Under the prospectus’s $0.031 pricing assumption, the SPP or its shortfall would issue 64.52 million new shares. A shareholder who does not participate would face approximately 12.7% dilution, with the impact potentially higher if the final SPP price is lower or oversubscriptions are accepted. If all of the new and existing relevant options were exercised, the stated aggregate dilutionary impact would rise to 38.12% under the same assumptions.
Shareholder approval is required for the SPP securities, shortfall securities, placement options, lead manager options and underwriter options. The general meeting is scheduled for 29 October, after the SPP closes on 23 October and the shortfall process begins. The company expects the SPP shares and Underwriter Options to be quoted around 2 November, subject to ASX approval, while the other new options will remain unquoted.
Bottom Line?
ABx is buying project runway with fresh equity, but the investment case now turns on approval, final pricing, funding duration and whether the conflicting Underwriter Option terms are corrected.
Questions in the middle?
- Will shareholders approve all of the interdependent securities issues at the 29 October meeting?
- What will the final SPP price be relative to ABx’s market price when the shares are issued?
- Can the expanded cash balance carry Deep Leads and ALCORE to meaningful milestones before further funding is required?